Male participants (even if surgically sterilized), and partners who are women of childbearing potential must be using highly effective contraception in addition to a barrier method throughout the study drug treatment period and for  days after the final study drug administration.
Male subject who is of childbearing potential and their female spouse/partner who is of childbearing potential must be using highly effective contraception consisting of  forms of birth control (at least one of which must be a barrier method) starting at screening and continue throughout the study, and for  days after the final study drug administration.
Male subject and their female spouse/partners who are of childbearing potential must be using highly effective contraception* consisting of  forms of birth control (at least one of which must be a barrier method) starting at Screening and continue throughout the study period, and for  months after the final study drug administration
Male subject has not had a vasectomy or is not sterile as defined below, subject's female partner(s) is utilizing  form of highly effective birth control*starting at Screening and continue throughout study treatment and for  months after the subject receives final study drug administration
Male subject and their female partners who are of childbearing potential must be using highly effective contraception per locally accepted standards in addition to a barrier method starting at Screening and continue throughout the study period and for  days after the final study drug administration.
Male subject and their female spouse/partners who are of childbearing potential must be using highly effective contraception consisting of two forms of birth control (at least one of which must be a barrier method) starting at Screening and continue throughout the study period, and for  days after the final study drug administration.
Male subject and their female partners who are of childbearing potential must be using  forms of effective contraception per locally accepted standards,  of which must be a barrier method, starting at screening and continue throughout the study period, and for  days after the final study drug administration.
Male subject and their female spouse/partners who are of childbearing potential must be using highly effective contraception consisting of two forms of birth control* (one of which must be a barrier method) starting at Screening and continue throughout the study period and for  days after the final study drug administration.
Male subject and their female spouse/partners who are of childbearing potential must be using highly effective contraception consisting of  forms of birth control ( of which must be a barrier method) starting at Screening and continue throughout the study period and for  days after the final study drug administration.
Subjects and spouse/partner who are of childbearing potential must be using high effective contraception consisting of  forms of birth control (at least  of which much be barrier method) starting at Screening and continuing through the entire study (for at least  months after the last dose of ALXN if study treatment is stopped early or subject withdraws consent).
Agrees to use a male condom starting at screening and continue throughout study treatment and for  days after the final study drug administration. If the male subject has not had a vasectomy or is not sterile as defined below their female partner(s) is utilizing  form of highly effective birth control*starting at screening and continue throughout study treatment and for  days after the male subject receives their final study drug administration.
Male subject and their female spouse/partners who are of childbearing potential must be using highly effective contraception consisting of  forms of birth control
Male subject and a female spouse/partner who is of childbearing potential must be using highly effective contraception consisting of  forms of birth control (one of which must be a barrier method) starting at screening and continue throughout the study period and for  days after the final study drug administration.
Male subject and their female spouse/partners who are of childbearing potential must be using highly effective contraception consisting of two forms of birth control (one of which must be a barrier method) starting at Screening and continue throughout the study period and for  days after the final study drug administration.
Male subject and his female spouse/partner who is of childbearing potential must be using highly effective contraception consisting of two forms of birth control* (one of which must be a barrier method) starting at screening and continue throughout the study period and for  days after the final study drug administration.
Male patients must use highly effective contraception methods consisting of  forms of birth control (at least  of which must be a barrier method) starting at screening and continuing throughout the study period and for  days after the final study drug administration.
Subject and female partner who is of childbearing potential must continue to use  forms of birth control, of which  must be highly effective and  must be a barrier method throughout the study and for  months after final enzalutamide administration.
Male subject and subject's female partners who are of childbearing potential must be using highly effective contraception per locally accepted standards (in addition to a barrier method) starting at screening and continue throughout the study period and for  months and  week after the final study drug administration.